NEW YORK (TheStreet) -- Vertex Pharmaceuticals (VRTX - Get Report) soared to a 52-week high of $98.80 on Tuesday after the company reported extremely positive results from two crucial Phase III trials.
Vertex reported statistically significant lung function improvement in patients with the most common form of cystic fibrosis after a combination therapy of two drugs VX-809, also known as lumacaftor, and Kalydeco. The two studies, called "Traffic" and "Transport," each met their primary endpoints separately.
When considered together together, cystic fibrosis patients treated with the greater of two doses of VX-809 and Kalydeco showed a 3.3% improvement in lung function on an absolute basis compared to placebo.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts